Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis
NCT07895524 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Participants With Rheumatoid Arthritis
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 23, 2026
- Completion date
- November 28, 2028
- Enrollment
- 60 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis
Arms
As registered; 3 arms.
-
Period 1: MK-8690
Participant will receive MK-8690 subcutaneous (SC) for 12 weeks
-
Period 1: Placebo
Participant will receive placebo SC for 12 weeks
-
Extension Period
After completing Period 1 participants will receive MK-8690 SC for 40 weeks.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50) at Week 12
ACR response is a well-established composite measure used in clinical trials to evaluate clinical response in rheumatoid arthritis (RA). ACR50 response is defined as 50% or greater improvement in tender joint count (TJC) based on 68 joints, swollen joint count (SJC) based on 66 joints, and ≥3 of the 5 remaining components of Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment of Disease Activity (PGA), Patient Global Assessment of Disease Activity (PtGA), Patient Assessment of Pain Severity, and high-sensitivity C-reactive protein (hsCRP). ACR50 is an accepted measure by the FDA to demonstrate reduction in RA disease activity and is defined as the proportion of participants achieving 50% improvement in the composite measure. The percentage of participants achieving ACR50 at Week 12 will be presented.
Lead sponsor's other trials
Merck Sharp & Dohme LLC, most recent start first.
+2,160 more trials
Similar trials
Same condition (Arthritis, Rheumatoid) and phase, most recent start first.
+451 more trials See the condition page